Sofwave Medical Reports First Quarter Fiscal 2026 Financial Results and Business Highlights
Sofwave Medical Ltd reported a 46% year-over-year revenue increase to $24.4 million for Q1 2026, driven by rising treatment adoption and a 56% growth in recurring usage fees. The company is focused on redefining aesthetic treatments with non-invasive solutions, particularly catering to patients on GLP-1 therapies. Operating expenses as a percentage of revenue decreased from 78% to 67% year-over-year, demonstrating efficiency improvements.
SAN CLEMENTE, Calif., May 05, 2026 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the three-month period ended March 31, 2026, and recent business highlights.